| Developmentally regulated and tissue specific expression of mRNAs encoding the two alternative forms of the LIM domain oncogene rhombotin: evidence for thymus expression. | None |
| The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors. | None |
| Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex. | None |
| This article demonstrates a novel and unexpected function of the LMO2 oncogenic transcription factor in controlling DNA replication that we unravelled via an unbiased proteome-wide screen for LMO2-interacting partners. | None |
| Transient LMO2 expression is sufficient for oncogenic function and induction of T-ALL. The resulting T-ALLs lacked LMO2 and its target-gene expression, and histologically, transcriptionally, and genetically similar to human LMO2-driven T-ALL. | None |
| Expression of the proto-oncogene rhombotin-2 is identical to the acute phase response protein metallothionein, suggesting multiple functions. | None |
| The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. | None |
| The TTG-2/RBTN2 T cell oncogene encodes two alternative transcripts from two promoters: the distal promoter is removed by most 11p13 translocations in acute T cell leukaemia s (T-ALL). | None |
| The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. | None |
| T-cell proto-oncogene rhombotin-2 is a complex transcription regulator containing multiple activation and repression domains. | None |
| The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells. | None |